Equities Analysts Offer Predictions for MLTX Q2 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for shares of MoonLake Immunotherapeutics in a research report issued on Thursday, February 27th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings per share of ($0.82) for the quarter. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for MoonLake Immunotherapeutics’ Q3 2025 earnings at ($0.80) EPS, Q4 2025 earnings at ($0.78) EPS and FY2029 earnings at $7.54 EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.09).

Several other research firms also recently weighed in on MLTX. HC Wainwright restated a “buy” rating and issued a $100.00 target price on shares of MoonLake Immunotherapeutics in a research report on Thursday. The Goldman Sachs Group lowered their target price on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a “buy” rating on the stock in a research note on Thursday. Wedbush restated an “outperform” rating and set a $73.00 price target (down from $92.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, November 5th. Finally, Needham & Company LLC increased their price objective on shares of MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the company a “buy” rating in a report on Thursday. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $83.20.

MoonLake Immunotherapeutics Trading Down 1.4 %

Shares of MoonLake Immunotherapeutics stock opened at $41.77 on Friday. MoonLake Immunotherapeutics has a twelve month low of $37.55 and a twelve month high of $58.26. The firm has a market capitalization of $2.67 billion, a PE ratio of -32.38 and a beta of 1.28. The firm’s 50-day moving average price is $46.90 and its 200 day moving average price is $48.99.

Institutional Trading of MoonLake Immunotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. US Bancorp DE purchased a new position in shares of MoonLake Immunotherapeutics during the third quarter worth $44,000. Deutsche Bank AG lifted its stake in MoonLake Immunotherapeutics by 59.8% during the 4th quarter. Deutsche Bank AG now owns 903 shares of the company’s stock worth $49,000 after acquiring an additional 338 shares in the last quarter. Birchview Capital LP purchased a new position in MoonLake Immunotherapeutics during the 4th quarter valued at about $217,000. KLP Kapitalforvaltning AS acquired a new position in MoonLake Immunotherapeutics in the 4th quarter valued at about $244,000. Finally, PEAK6 LLC acquired a new position in MoonLake Immunotherapeutics in the 4th quarter valued at about $271,000. 93.85% of the stock is owned by institutional investors and hedge funds.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.